Identifying neuroimaging based biomarkers for predicting clinical progression along the Lewy Body disease spectrum

识别基于神经影像的生物标志物，用于预测路易体疾病谱的临床进展

• 批准号: nhmrc : GNT1151722
• 负责人: Dr Elie Matar
• 金额: $ 12.64万
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/identifying-neuroimaging-based-disease-spectrum/1349005
• 关键词: Identifying; neuroimaging; based; biomarkers; predicting

Lewy body dementias (LBD) comprise similar but heterogenous group of poorly understood disabling neurodegenerative conditions. This project aims to apply advanced neuroimaging techniques and novel psychological testing to patients at risk of Lewy body disorders as well individuals with established disease to identify novel biomarkers that may explain symptoms of these disorders as well as help predict development of LBD at its early stages when it may be amenable to neuroprotective treatments.

路易体痴呆(LBD)包括一组相似但异质性的致残性神经退行性疾病。该项目旨在将先进的神经成像技术和新的心理测试应用于有路易体疾病风险的患者以及已有疾病的患者，以确定可能解释这些疾病症状的新生物标记物，并帮助预测LBD的早期发展，当时它可能适合神经保护治疗。